Phase 3 lidERA evaluates daily oral SERD giredestrant in ER+/HER2- early disease, including subgroup analyses by age and menopausal status after a reported 30% risk reduction. Primary ASCENT-04 data ...
Prosigna identified a large high-clinical-risk subgroup with minimal chemotherapy benefit, estimated to avert at most two recurrences per 100 patients treated. Enrollment broadened prior assay use by ...
Final Phase 2 Bria-IMT median overall survival (OS) is 16.6 months (with Phase 3 formulation) Positive Quality of Life (QOL) data from the ...
Anitocabtagene autoleucel is an investigational therapy. Neither Kite or Arcellx has received approval from any regulatory authority for any use of this therapy, and its safety and efficacy has not ...
Breast cancer is the second leading cause of cancer death among women, according to the American Cancer Society. Now, three recent studies by researchers at Sylvester Comprehensive Cancer Center, part ...
Most breast cancer patients in Uganda and Ethiopia are diagnosed too late, and many lack access to life-saving treatment. Tove Ekdahl Hjelm defends her thesis "Early-onset breast cancer in East Africa ...
Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced that new data from a retrospective ...
SAN FRANCISCO and SUZHOU, China, June 2, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and ...
- Company Will Discuss Data and Report First Quarter 2026 Financial Results on May 8 - SOUTH SAN FRANCISCO, Calif., April 30, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. ("ALX Oncology"; ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results